Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into emergence and spread of multidrug resistance
暂无分享,去创建一个
Thomas Abeel | James E. Galagan | Andrei Gabrielian | Alex Rosenthal | Ted Cohen | Parissa Farnia | David Alland | Bruce W. Birren | Po-Ren Hsueh | Alex Salazar | Laura E. Via | Abigail L. Manson | Ashlee M. Earl | Sujatha Narayanan | Christopher A. Desjardins | Valeriu Crudu | Gail H. Cassell | B. Birren | S. Dorman | J. Galagan | W. Bishai | S. Swaminathan | A. Gabrielian | D. Alland | M. L. van der Walt | Sang-Nae Cho | A. Rosenthal | T. Cohen | A. Earl | T. Abeel | J. Ellner | A. Velayati | S. Chapman | C. Desjardins | P. Hsueh | L. Via | C. Barry | K. Winglee | M. Joloba | A. Pym | S. Narayanan | D. Armstrong | W. Ssengooba | A. Skrahina | V. Crudu | P. Juréen | S. Hoffner | William R. Bishai | Soumya Swaminathan | Daniela Homorodean | M. Maiga | A. Manson | G. Cassell | Kathryn Winglee | James Gomez | Clifton E. Barry | Jong Seok Lee | Sven Hoffner | Sang-Nae Cho | Keira A. Cohen | Derek T. Armstrong | Jeannette Brand | Sinéad B. Chapman | Andreea M. Jodals | Moses Joloba | Pontus Jureen | Lesibana Malinga | Mamoudou Maiga | Dale Nordenberg | Ecaterina Noroc | Elena Romancenco | Willy Ssengooba | A. A. Velayati | Aksana Zalutskaya | Susan E. Dorman | Jerrold Ellner | Alexander S. Pym | Alena Skrahina | Martie Van der Walt | P. Farnia | A. Zalutskaya | K. Cohen | Alex N. Salazar | E. Romancenco | M. Walt | J. Brand | L. Malinga | D. Homorodean | E. Noroc | James Gomez | Dale Nordenberg | Jeannette Pontus Lesibana Dale A A Gail H Parissa Daniela Ma Brand Jureen Malinga Nordenberg Velayat | P. Juréen | Elena Romancenco
[1] A. Nunn,et al. Global tuberculosis drug development pipeline: the need and the reality , 2010, The Lancet.
[2] Jukka Corander,et al. Evolution and transmission of drug resistant tuberculosis in a Russian population , 2014, Nature Genetics.
[3] C. Daborn,et al. The epidemiology of Mycobacterium bovis infections in animals and man: a review. , 1995, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[4] Dick van Soolingen,et al. Epidemiology of Isoniazid Resistance Mutations and Their Effect on Tuberculosis Treatment Outcomes , 2013, Antimicrobial Agents and Chemotherapy.
[5] R. Kao,et al. Whole Genome Sequencing Reveals Local Transmission Patterns of Mycobacterium bovis in Sympatric Cattle and Badger Populations , 2012, PLoS pathogens.
[6] A. Benedetti,et al. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. , 2017, The Lancet. Infectious diseases.
[7] A. Catanzaro,et al. Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis: A Systematic Review , 2015, PloS one.
[8] M. Suchard,et al. Bayesian Phylogenetics with BEAUti and the BEAST 1.7 , 2012, Molecular biology and evolution.
[9] K. Dooley,et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] P. Small,et al. Impact of Bacterial Genetics on the Transmission of Isoniazid-Resistant Mycobacterium tuberculosis , 2006, PLoS pathogens.
[11] Nalin Rastogi,et al. Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage , 2015, Nature Genetics.
[12] W. Fawzi,et al. Multi Drug and Other Forms of Drug Resistant Tuberculosis Are Uncommon among Treatment Naïve Tuberculosis Patients in Tanzania , 2015, PloS one.
[13] W. Jacobs,et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. , 1994, Science.
[14] Raymund B. Dantes,et al. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] D. Hughes,et al. Genetic characterization of compensatory evolution in strains carrying rpoB Ser531Leu, the rifampicin resistance mutation most frequently found in clinical isolates. , 2013, The Journal of antimicrobial chemotherapy.
[16] A. Aseffa,et al. Mycobacterium tuberculosis Lineage 7 Strains Are Associated with Prolonged Patient Delay in Seeking Treatment for Pulmonary Tuberculosis in Amhara Region, Ethiopia , 2015, Journal of Clinical Microbiology.
[17] G. Alangaden,et al. Mechanism of Resistance to Amikacin and Kanamycin in Mycobacterium tuberculosis , 1998, Antimicrobial Agents and Chemotherapy.
[18] A. Zaha,et al. Characterization of pncA Mutations in Pyrazinamide-Resistant Mycobacterium tuberculosis in Brazil , 2005, Antimicrobial Agents and Chemotherapy.
[19] Ying Zhang,et al. pncA Mutations as a Major Mechanism of Pyrazinamide Resistance in Mycobacterium tuberculosis: Spread of a Monoresistant Strain in Quebec, Canada , 2000, Antimicrobial Agents and Chemotherapy.
[20] P. Butcher,et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. , 2014, The New England journal of medicine.
[21] Peter Lackner,et al. MAESTRO - multi agent stability prediction upon point mutations , 2015, BMC Bioinformatics.
[22] S. Cole,et al. Missense mutations in the catalase‐peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis , 1995, Molecular microbiology.
[23] Adam P. Arkin,et al. FastTree: Computing Large Minimum Evolution Trees with Profiles instead of a Distance Matrix , 2009, Molecular biology and evolution.
[24] J. T. Crawford,et al. ethA, inhA, and katG Loci of Ethionamide-Resistant Clinical Mycobacterium tuberculosis Isolates , 2003, Antimicrobial Agents and Chemotherapy.
[25] H. Soini,et al. katG mutations in isoniazid-resistant Mycobacterium tuberculosis isolates recovered from Finnish patients , 1996, Antimicrobial agents and chemotherapy.
[26] L. Via,et al. Mutations in gidB Confer Low-Level Streptomycin Resistance in Mycobacterium tuberculosis , 2011, Antimicrobial Agents and Chemotherapy.
[27] J. T. Crawford,et al. Characterization of Spontaneous, In Vitro-Selected, Rifampin-Resistant Mutants of Mycobacterium tuberculosisStrain H37Rv , 2000, Antimicrobial Agents and Chemotherapy.
[28] J. Sacchettini,et al. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. , 1998, Science.
[29] J. Chien,et al. Treatment outcome of patients with isoniazid mono-resistant tuberculosis. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[30] S. Cole,et al. Streptomycin resistance in mycobacteria , 1994, Antimicrobial Agents and Chemotherapy.
[31] Julian Parkhill,et al. Inferring patient to patient transmission of Mycobacterium tuberculosis from whole genome sequencing data , 2013, BMC Infectious Diseases.
[32] M. Donald Cave,et al. Population Genetics Study of Isoniazid Resistance Mutations and Evolution of Multidrug-Resistant Mycobacterium tuberculosis , 2006, Antimicrobial Agents and Chemotherapy.
[33] W. Bishai,et al. Whole Genome Sequencing of Mycobacterium africanum Strains from Mali Provides Insights into the Mechanisms of Geographic Restriction , 2016, PLoS neglected tropical diseases.
[34] I. Bastian,et al. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2010. A report of the Australian Mycobacterium Reference Laboratory Network. , 2013, Communicable diseases intelligence quarterly report.
[35] M. Makino,et al. Characterization of the rpsL and rrs genes of streptomycin‐resistant clinical isolates of Mycobacterium tuberculosis in Japan , 1997, Journal of applied microbiology.
[36] A. Velayati,et al. High prevelance of rifampin-monoresistant tuberculosis: a retrospective analysis among Iranian pulmonary tuberculosis patients. , 2014, The American journal of tropical medicine and hygiene.
[37] I. Sugawara,et al. The molecular epidemiology of ethambutol-resistant Mycobacterium tuberculosis in Henan Province, China. , 2005, Japanese journal of infectious diseases (Print).
[38] Sonya S. Shin,et al. The dilemma of MDR-TB in the global era. , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[39] Victor DeGruttola,et al. Bayesian Estimation of Mixture Models with Prespecified Elements to Compare Drug Resistance in Treatment-Naïve and Experienced Tuberculosis Cases , 2013, PLoS Comput. Biol..
[40] H. Marrakchi,et al. InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II. , 2000, Microbiology.
[41] D. van Soolingen,et al. Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. , 2010, The Lancet. Infectious diseases.
[42] A. Diacon,et al. Early Bactericidal Activity of High-Dose Rifampin in Patients with Pulmonary Tuberculosis Evidenced by Positive Sputum Smears , 2007, Antimicrobial Agents and Chemotherapy.
[43] Yuqing Li,et al. Characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Sichuan in China. , 2013, Tuberculosis.
[44] Thomas Abeel,et al. Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance , 2016, Nature Genetics.
[45] Razvan Sultana,et al. Genomic Analysis Identifies Targets of Convergent Positive Selection in Drug Resistant Mycobacterium tuberculosis , 2013, Nature Genetics.
[46] W. Jacobs,et al. Genetic Manipulation of Mycobacterium tuberculosis , 2007, Current protocols in microbiology.
[47] Marc Lipsitch,et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug resistant tuberculosis , 2013, Nature Genetics.
[48] K. Yuen,et al. Molecular Characterization of Isoniazid Resistance in Mycobacterium tuberculosis: Identification of a Novel Mutation in inhA , 2006, Antimicrobial Agents and Chemotherapy.
[49] J. Farrar,et al. Mutations Prevalent among Rifampin- and Isoniazid-Resistant Mycobacterium tuberculosis Isolates from a Hospital in Vietnam , 2006, Journal of Clinical Microbiology.
[50] E. Rubin,et al. Genes required for mycobacterial growth defined by high density mutagenesis , 2003, Molecular microbiology.
[51] M. Chase,et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection , 2011, Nature Genetics.
[52] K. Feldmann,et al. Geographic variation of the predictive values of genomic mutations associated with streptomycin resistance in Mycobacterium tuberculosis. , 1997, Molecular and cellular probes.
[53] I. Bastian,et al. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2001. , 2003, Communicable diseases intelligence quarterly report.
[54] Ying Zhang,et al. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus , 1996, Nature Medicine.
[55] Stefan Niemann,et al. Variable host-pathogen compatibility in Mycobacterium tuberculosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[56] R. Hasan,et al. High Isoniazid Resistance Rates in Rifampicin Susceptible Mycobacterium tuberculosis Pulmonary Isolates from Pakistan , 2012, PloS one.
[57] F. Balloux,et al. Four decades of transmission of a multidrug-resistant Mycobacterium tuberculosis outbreak strain , 2015, Nature Communications.
[58] Paul van Helden,et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study , 2014, The Lancet.
[59] J. V. van Horn,et al. Penetration of isoniazid, rifampicin and pyrazinamide in tuberculous pleural effusion and psoas abscess. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[60] J. Musser,et al. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms , 1997, Antimicrobial agents and chemotherapy.
[61] P. Massoure,et al. Significance of the Identification in the Horn of Africa of an Exceptionally Deep Branching Mycobacterium tuberculosis Clade , 2012, PloS one.
[62] M. Reed,et al. Major Mycobacterium tuberculosis Lineages Associate with Patient Country of Origin , 2009, Journal of Clinical Microbiology.
[63] T. Clark,et al. Recurrence due to Relapse or Reinfection With Mycobacterium tuberculosis: A Whole-Genome Sequencing Approach in a Large, Population-Based Cohort With a High HIV Infection Prevalence and Active Follow-up , 2014, The Journal of infectious diseases.
[64] A. Khomenko,et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. , 2000, JAMA.
[65] Steven J. M. Jones,et al. Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. , 2011, The New England journal of medicine.
[66] T. Sterling,et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. , 2012, The Journal of antimicrobial chemotherapy.
[67] A. Telenti,et al. Role of embB in natural and acquired resistance to ethambutol in mycobacteria , 1997, Antimicrobial agents and chemotherapy.
[68] E. Böttger,et al. Genetic alterations in streptomycin-resistant Mycobacterium tuberculosis: mapping of mutations conferring resistance , 1994, Antimicrobial Agents and Chemotherapy.
[69] P. Klatser,et al. Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance , 2009, The Journal of antimicrobial chemotherapy.
[70] H. Mills,et al. Community-Wide Isoniazid Preventive Therapy Drives Drug-Resistant Tuberculosis: A Model-Based Analysis , 2013, Science Translational Medicine.
[71] Thomas Abeel,et al. Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal , 2015, PLoS medicine.
[72] J. Childs,et al. A household-based, case-control study of environmental factors associated with hantavirus pulmonary syndrome in the southwestern United States. , 1995, The American journal of tropical medicine and hygiene.
[73] G. Bai,et al. The rpsL gene and streptomycin resistance in single and multiple drug‐resistant strains of Mycobacterium tuberculosis , 1993, Molecular microbiology.
[74] J C Sacchettini,et al. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. , 1995, Biochemistry.
[75] T. Sterling,et al. Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin- Mono-Resistant Pulmonary Tuberculosis in Lima, Peru , 2016, PloS one.
[76] Christina A. Cuomo,et al. Pilon: An Integrated Tool for Comprehensive Microbial Variant Detection and Genome Assembly Improvement , 2014, PloS one.
[77] J. Parkhill,et al. Large-scale whole genome sequencing of M. tuberculosis provides insights into transmission in a high prevalence area , 2015, eLife.
[78] Q. Zeng,et al. Evolution of extensively drug-resistant tuberculosis over four decades revealed by whole genome sequencing of Mycobacterium tuberculosis from KwaZulu-Natal, South Africa , 2015 .
[79] Daniel J. Wilson,et al. Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study , 2013, The Lancet. Infectious diseases.
[80] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[81] T. Sterling,et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. , 2009, American journal of respiratory and critical care medicine.
[82] Y. Hao,et al. GenoType MTBDRplus Assay for Rapid Detection of Multidrug Resistance in Mycobacterium tuberculosis: A Meta-Analysis , 2016, PloS one.
[83] Samuel A. Assefa,et al. Elucidating Emergence and Transmission of Multidrug-Resistant Tuberculosis in Treatment Experienced Patients by Whole Genome Sequencing , 2013, PloS one.
[84] H. Marttila,et al. pncA Mutations in Pyrazinamide-ResistantMycobacterium tuberculosis Isolates from Northwestern Russia , 1999, Antimicrobial Agents and Chemotherapy.
[85] M. Pai,et al. Do We Need to Detect Isoniazid Resistance in Addition to Rifampicin Resistance in Diagnostic Tests for Tuberculosis? , 2014, PloS one.
[86] E. Böttger,et al. Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot , 1993, Molecular microbiology.
[87] P. V. van Helden,et al. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[88] F. Portaels,et al. Relationship between Pyrazinamide Resistance, Loss of Pyrazinamidase Activity, and Mutations in the pncA Locus in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis , 1999, Antimicrobial Agents and Chemotherapy.
[89] C. Brandon Ogbunugafor,et al. Adaptive Landscape by Environment Interactions Dictate Evolutionary Dynamics in Models of Drug Resistance , 2016, PLoS Comput. Biol..
[90] H. Jenkins,et al. Quantifying the Burden and Trends of Isoniazid Resistant Tuberculosis, 1994–2009 , 2011, PloS one.
[91] R. Jou,et al. Performance Assessment of the GenoType MTBDRplus Test and DNA Sequencing in Detection of Multidrug-Resistant Mycobacterium tuberculosis , 2009, Journal of Clinical Microbiology.
[92] S. Niemann,et al. Significance of Mutations in embB Codon 306 for Prediction of Ethambutol Resistance in Clinical Mycobacterium tuberculosis Isolates , 2006, Antimicrobial Agents and Chemotherapy.
[93] G. Drusano,et al. Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin , 2007, Antimicrobial Agents and Chemotherapy.
[94] Andrew J. Oler,et al. Whole-Genome Sequencing of Mycobacterium tuberculosis Provides Insight into the Evolution and Genetic Composition of Drug-Resistant Tuberculosis in Belarus , 2016, Journal of Clinical Microbiology.
[95] D. Mitchison. Role of individual drugs in the chemotherapy of tuberculosis. , 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[96] Alex Salazar,et al. Normalizing alternate representations of large sequence variants across multiple bacterial genomes , 2015, BMC Bioinformatics.
[97] A. Telenti,et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis , 1993, The Lancet.
[98] Phelim Bradley,et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study , 2015, The Lancet. Infectious diseases.
[99] S. Cole,et al. Effect of katG Mutations on the Virulence of Mycobacterium tuberculosis and the Implication for Transmission in Humans , 2002, Infection and Immunity.
[100] D. van Soolingen,et al. Pre-Existing Isoniazid Resistance, but Not the Genotype of Mycobacterium Tuberculosis Drives Rifampicin Resistance Codon Preference in Vitro , 2012, PloS one.
[101] T. Hinkley,et al. Fitness Costs of Drug Resistance Mutations in Multidrug-Resistant Mycobacterium tuberculosis: A Household-Based Case-Control Study. , 2016, The Journal of infectious diseases.
[102] K. Kam,et al. Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong , 2007, The Journal of antimicrobial chemotherapy.
[103] A. Benedetti,et al. Standardized Treatment of Active Tuberculosis in Patients with Previous Treatment and/or with Mono-resistance to Isoniazid: A Systematic Review and Meta-analysis , 2009, PLoS medicine.
[104] T. Clark,et al. Unraveling Mycobacterium tuberculosis genomic diversity and evolution in Lisbon, Portugal, a highly drug resistant setting , 2014, BMC Genomics.
[105] Dan S. Tawfik,et al. Initial Mutations Direct Alternative Pathways of Protein Evolution , 2011, PLoS genetics.
[106] K. Jung,et al. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea. , 2001, Journal of Korean medical science.
[107] P. Beckert,et al. Detection of drug-resistant tuberculosis by Xpert MTB/RIF in Swaziland. , 2015, The New England journal of medicine.
[108] Eduardo Gotuzzo,et al. Rapid molecular detection of tuberculosis and rifampin resistance. , 2010, The New England journal of medicine.
[109] J. Pasipanodya,et al. A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. , 2011, Current opinion in pharmacology.
[110] M. Makino,et al. Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. , 1998, Journal of clinical microbiology.
[111] Dongfang Li,et al. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance , 2013, Nature Genetics.
[112] Robert C. Wolpert,et al. A Review of the , 1985 .
[113] George M Church,et al. Tuberculosis Drug Resistance Mutation Database , 2009, PLoS medicine.
[114] D. Snider,et al. U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. , 2015, The American review of respiratory disease.
[115] Stefan Niemann,et al. Whole Genome Sequencing versus Traditional Genotyping for Investigation of a Mycobacterium tuberculosis Outbreak: A Longitudinal Molecular Epidemiological Study , 2013, PLoS medicine.
[116] S. Gillespie,et al. The effect of oxidative stress on the mutation rate of Mycobacterium tuberculosis with impaired catalase/peroxidase function. , 2008, The Journal of antimicrobial chemotherapy.
[117] Y. Kazumi,et al. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. , 1997, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[118] K. Holt,et al. Out-of-Africa migration and Neolithic co-expansion of Mycobacterium tuberculosis with modern humans , 2013, Nature Genetics.
[119] N. Awofeso. Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment. , 2008, Bulletin of the World Health Organization.
[120] P. Schultz,et al. Mechanistic Studies of the Oxidation of Isoniazid by the Catalase Peroxidase from Mycobacterium tuberculosis , 1994 .
[121] H. Soini,et al. A Ser315Thr Substitution in KatG Is Predominant in Genetically Heterogeneous Multidrug-Resistant Mycobacterium tuberculosis Isolates Originating from the St. Petersburg Area in Russia , 1998, Antimicrobial Agents and Chemotherapy.
[122] A. Rahmo,et al. Genotypic detection of rifampicin-resistant M. tuberculosis strains in Syrian and Lebanese patients. , 2012, Journal of infection and public health.
[123] K. Wan,et al. Prevalence of mutations conferring resistance among multi- and extensively drug-resistant Mycobacterium tuberculosis isolates in China , 2015, The Journal of Antibiotics.
[124] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.